Share Twitter LinkedIn Facebook Email Peter M. Voorhees, MD @LevineCancer shares the current thinking regarding treatment algorithms in relapsed/refractory multiple myeloma.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read
